Comparison · NCT01263509-sae
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID vs Alogliptin 25 mg QD and Voglibose 0.2 mg TID: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID vs Alogliptin 25 mg QD and Voglibose 0.2 mg TID: serious adverse events. Trial comparisons, record NCT01263509-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01263509-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0556 | 0.0257 | 0.116 | wilson | |
| Risk in group 2 | 0.0667 | 0.0327 | 0.131 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0111 | -0.0823 | 0.0582 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.29 | 2.4 | log | |
| Odds ratio, group 1 over group 2 | 0.824 | 0.267 | 2.54 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID than on Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 90 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. | 6 | 108 | EG000 |
| Group 2 | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. | 7 | 105 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment-emergent adverse events are adverse events that started after the first dose of study drug and the last dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
- NCT number
- NCT01263509
- Phases
- PHASE2, PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Alogliptin and voglibose, Alogliptin and voglibose
- Lead sponsor
- Takeda
- Results first posted
- 2011-08-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01263509?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01263509-sae